Pharmacokinetic Similarity between Biosimilar Insulin Aspart Premix SAR341402 Mix 70/30 and Originator Insulin Aspart Mix 70/30 (NovoMix 30) in Indian Adults with Type 2 Diabetes: GEMELLI M Substudy

BACKGROUND: We compared the pharmacokinetic exposure, efficacy, safety and immunogenicity of biosimilar insulin aspart premix SAR341402 Mix 70/30 (SAR(Asp)-Mix) with its originator NovoMix(®) 30 insulin aspart mix (NN-Mix) in adults with type 2 diabetes. METHODS: This was a randomized, open-label, p...

Descripción completa

Detalles Bibliográficos
Autores principales: Mohan, Viswanathan, Schmider, Wolfgang, Singh, Kiran P., Rotthaeuser, Baerbel, Mukherjee, Bhaswati, Aravind, S. R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9519840/
https://www.ncbi.nlm.nih.gov/pubmed/36185965
http://dx.doi.org/10.4103/ijem.ijem_216_22

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9519840/
https://www.ncbi.nlm.nih.gov/pubmed/36185965
http://dx.doi.org/10.4103/ijem.ijem_216_22

Ejemplares similares